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Abstract
Ambulatory blood pressure monitoring offers the ability to collect blood pressure readings several 
times an hour across a 24-hour period. Ambulatory blood pressure monitoring facilitates the 
identification of white-coat hypertension, the phenomenon whereby certain individuals who are 
not on antihypertensive medication show elevated blood pressure in a clinical setting but show 
non-elevated blood pressure averages when assessed by ambulatory blood pressure monitoring. 
Additionally, readings can be segmented into time windows of particular interest, e.g., mean 
daytime and nighttime values. During sleep, blood pressure typically decreases, or dips, such that 
mean sleep blood pressure is lower than mean awake blood pressure. A non-dipping pattern and 
nocturnal hypertension are strongly associated with increased cardiovascular morbidity and 
mortality. Approximately 70% of individuals dip ≥10% at night, while 30% have non-dipping 
patterns, when blood pressure remains similar to daytime average, or occasionally rises above 
daytime average. The various blood pressure categorizations afforded by ambulatory blood 
pressure monitoring are valuable for clinical management of high blood pressure since they 
increase accuracy for diagnosis and the prediction of cardiovascular risk.
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High blood pressure is currently the greatest threat to the global burden of disease.1–3 
Hypertension continues to be the most common diagnosis in adult primary care practice as 
well as the most salient cardiovascular disease risk factor. Recent figures published by the 
American Heart Association's Statistics Committee and Stroke Statistics Subcommittee, 
based on 2007–2010 data, revealed that 33% of adults ≥ 20 years of age in the United States 
have hypertension, i.e., almost 80 million people (the prevalence is similar for both sexes).4 
Fortunately, antihypertensive treatment substantially reduces the risk of heart failure, 
myocardial infarction, and stroke.5
Blood pressure measurements are essential for clinicians in the diagnosis and treatment of 
hypertension.6 Choosing the most informative blood pressure assessment methodology is 
therefore a topic of fundamental importance. Pickering and colleagues7 observed that "Any 
clinical measurement of blood pressure may be regarded as a surrogate measure for the 
"true" blood pressure of the patient, which may be defined as the mean level over prolonged 
periods." Compared with the traditional method of taking a small number of readings in a 
clinical setting, ambulatory blood pressure monitoring offers the ability to collect blood 
pressure readings several times an hour across a 24-hour period. These readings can be 
aggregated to yield 24-hour means and also grouped into time windows (e.g., mean daytime 
and nighttime values). The various blood pressure categorizations facilitated by ambulatory 
blood pressure monitoring are valuable for clinical management of high blood pressure since 
they increase accuracy for diagnosis and the prediction of cardiovascular risk.8 Several 
recent guidelines discuss the employment of ambulatory blood pressure monitoring in 
clinical practice (Table 1).9–16
Given the rapidly expanding and diverse literature on ambulatory blood pressure monitoring, 
this paper provides a narrative review of the underlying rationale for its employment in 
clinical practice, its strengths and limitations, and the directions it may take in clinical 
practice in the coming years.
FUNDAMENTALS OF AMBULATORY BLOOD PRESSURE MONITORING
As noted in the Introduction, ambulatory blood pressure monitoring generates much more 
information than the single (typically daytime) 'snapshot in time' reading yielded by clinic 
measurement by providing a profile of blood pressure behavior over a 24-hour (or longer17) 
period, and, therefore, how blood pressure throughout this period can be beneficially 
influenced by antihypertensive therapy. The challenges, limitations, and questionable 
veracity of (office) blood pressure measurement have been extensively discussed.7,18,19 It is 
now well documented that ambulatory blood pressure monitoring provides superior 
prediction of cardiovascular outcomes, as discussed shortly.
As well as facilitating blood pressure assessment aggregated over the entire 24-hour period, 
ambulatory blood pressure monitoring also allows more fine-tuned assessments during 
specific windows of this time cycle. The circadian cycle can be divided into various periods: 
assessments at different times permit evaluation of circadian variation in blood pressure (see 
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Figure). Nighttime blood pressure is one of the most important measures of this circadian 
variation. Normally during sleep, blood pressure decreases ('dips') such that sleep average 
blood pressure is lower than average awake blood pressure. The 'normal' dip is considered 
10%–20%. Individuals who dip <10% are said be nondippers. Nocturnal hypertension and 
non-dipping pattern are strongly associated with increased cardiovascular morbidity and 
mortality. Around 70% of individuals show reduced blood pressure at night (i.e., show 
dipping ≥10%), and about 30% have non-dipping patterns, when blood pressure remains 
similar to daytime average, or occasionally rises above daytime average (reverse dippers). 
Other important parameters of blood pressure assessment facilitated by ambulatory blood 
pressure monitoring are the morning surge, when blood pressure increases rapidly from 
nighttime levels to daytime levels, and blood pressure variability.
Both hardware and software considerations are important for successful and optimally 
informative implementation of ambulatory blood pressure monitoring. First, monitors should 
be validated according to internationally accepted protocols. The International Protocol of 
the European Society of Hypertension20,21 is now the protocol that is used most commonly 
for the independent validation of devices.22 Second, while it is essential that appropriate 
hardware be utilized, it is equally, and arguably more, important that appropriately 
informative software be employed.23
Several papers provide informative summaries of ambulatory blood pressure monitoring 
techniques.7,23–25 Considerably more detailed discussion can be found in the European 
Society of Hypertension's 2013 position paper on ambulatory blood pressure monitoring.14
PREDICTION OF CLINICAL OUTCOMES
In a seminal study, Perloff and colleagues26 examined follow-up data for more than 1,000 
hypertensive individuals who had initially been evaluated with both office measurements and 
ambulatory blood pressure monitoring: both sexes were equally represented. The mean 
(±SD) initial office blood pressures were 161.2±22.6/100.7±12.1 mm Hg, and the mean 
ambulatory blood pressures were 145.6±22.3/91.5±13.7 mm Hg. Ambulatory blood pressure 
monitoring was found to be an independent prognostic indicator when assessing the overall 
risk profile of individual patients: those patients whose ambulatory blood pressure 
monitoring values were higher than predicted via regression analysis from their office blood 
pressure measurements (systolic blood pressure ≥ 10 mmHg higher or diastolic blood 
pressure ≥ 6 mmHg higher) had statistically significantly higher cumulative mortality and 
morbidity over 10 years than those whose ambulatory blood pressure monitoring values 
were lower than predicted (systolic blood pressure ≥ 10 mmHg lower or diastolic blood 
pressure ≥ 6 mmHg lower). These findings extended research by the same group 
demonstrating that among patients with similar office blood pressure measurements, those 
with relatively higher ambulatory blood pressure monitoring values had a greater prevalence 
of target-organ damage, including retinopathy and left ventricular hypertrophy. Ambulatory 
blood pressure monitoring was therefore considered superior to traditional office blood 
pressure measurements in this regard.26Across the subsequent three decades, other data have 
supported these authors' assertion of ambulatory blood pressure monitoring's superiority in 
predicting various outcomes.
Turner et al. Page 3





















Mancia and colleagues27 provided longitudinally controlled evidence across 12 months that 
ambulatory blood pressure monitoring better predicted antihypertensive treatment-induced 
regression of left ventricular hypertrophy than did clinic blood pressure. Verdecchia and 
colleagues28 provided extended discussions of the clinical applicability of results from 
longitudinal studies.
CLINICAL PRACTICE
Ambulatory blood pressure monitoring may be differentially useful in clinical practice 
according to whether or not an individual patient is being treated for hypertension.28 For 
untreated patients who have a clinical diagnosis of high blood pressure based on office 
readings, ambulatory blood pressure monitoring can categorize individuals at various levels 
of cardiovascular risk that would not be possible on the basis of the office readings alone: 
these risks may be low (the patient is demonstrating white-coat hypertension: see discussion 
shortly) or high (the patient is demonstrated sustained hypertension). Such determination of 
risk is a key factor in the clinical decision to commence antihypertensive treatment.29 For 
patients who have started antihypertensive treatment, ambulatory blood pressure monitoring 
facilitates individual tailoring of treatment regimens, which can be particularly helpful in 
cases of apparent drug resistance, excessive variability in multiple clinical readings, 
symptoms of hypotension despite apparently normal clinic blood pressure readings, and 
marked discrepancies between in-office and out-of-office blood pressure readings.28
While noting these strengths of ambulatory blood pressure monitoring, it should be made 
clear that we are not recommending broad ambulatory blood pressure monitoring should 
completely replace clinic blood pressure assessments.
White-coat Hypertension
White-coat hypertension is the phenomenon whereby certain individuals who are not on 
antihypertensive medication show elevated blood pressure in a clinical setting but show a 
non-elevated blood pressure average when assessed by ambulatory blood pressure 
monitoring:30 it occurs in 15%–30% of individuals with elevated office blood pressure 
readings.31 White-coat hypertension is more frequent in various categories of patients, 
including older adults, women, nonsmokers, and individuals without evidence of target 
organ damage.31 The misdiagnosis of white-coat hypertension as true hypertension has 
various undesirable consequences, including patients unnecessarily taking chronic 
medications, at considerable expense, with potentially seriously debilitating side 
effects.31, 32 Based on the finding that ambulatory blood pressure monitoring was the most 
cost-effective strategy for the diagnosis of hypertension because it avoids unnecessary 
treatment of white-coat hypertension,32 United Kingdom guidelines now recommend 
ambulatory blood pressure monitoring for all patients before diagnosing hypertension.9 The 
identification of occurrences of white-coat hypertension via ambulatory blood pressure 
monitoring therefore has considerable benefits at both the individual patient and the public 
health levels.
Consider the following case study. Mrs. Smith (pseudonym) is a 45 year-old, generally 
healthy woman who presents to clinic as a new patient for a “routine checkup.” Except for 
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an elevated clinic blood pressure that was 152/92 mm Hg at check-in when taken by the 
medical assistant and 150/95 mm Hg when taken manually by the physician, the physical 
exam is unremarkable. The patient reports that, in the past, she has taken her blood pressure 
using her mother’s home blood pressure monitor, and her values are “always below 140/90 
[mm Hg].” Mrs. Smith asks you about whether she needs further evaluation or treatment. In 
this case, performing ambulatory blood pressure monitoring to exclude white-coat 
hypertension before commencing antihypertensive treatment would be advantageous.
White-coat Effect in Resistant Hypertension
A white-coat effect can also occur in patients with treated hypertension, and is particularly 
relevant to the evaluation of patients with possible resistant hypertension. Many patients 
appear to have resistant hypertension based on their office blood pressure measurements but 
actually have controlled blood pressure when assessed by ambulatory blood pressure 
monitoring. In one study of over 600 patients with uncontrolled office blood pressure (i.e., 
>140 mmHg systolic blood pressure or >90 mmHg diastolic blood pressure), nearly 40% of 
those on one or two medications and almost 30% of those on three medications had 
controlled blood pressure on ambulatory blood pressure monitoring.33 In a Spanish study of 
over 8,200 patients with resistant hypertension, 38% were attributed to white-coat effect 
based on ambulatory blood pressure monitoring.34 Thus, ambulatory blood pressure 
monitoring is indicated for patients suspected of having resistant hypertension before 
increasing doses of current medications or adding additional blood pressure-lowering 
medication. See White et al35 for more detailed discussion of the use of ambulatory blood 
pressure monitoring in the diagnosis and treatment of resistant hypertension.
Masked Hypertension
Masked hypertension is the phenomenon whereby certain individuals who are not on 
antihypertensive medication show non-elevated blood pressure in a clinical setting but show 
high blood pressure when out of the office, typically assessed by ambulatory blood pressure 
monitoring: approximately 15–30% of adults with non-elevated office blood pressure have 
masked hypertension.36 Since masked hypertension is associated with increased risks of 
cardiovascular morbidity and mortality, clinic readings may therefore underestimate an 
individual's cardiovascular risk.7 For example, left ventricular mass index and carotid plaque 
are similar between people with masked hypertension and those with sustained 
hypertension.37,38 A meta-analysis of 7 studies including a total of 11,502 participants 
followed over 8 years showed a two-fold higher incidence of cardiovascular disease events 
(HR = 2.00; 95% CI 1.58–2.52) in people with masked hypertension compared with those 
with normal blood pressure (i.e., normal clinic blood pressure and normal ambulatory blood 
pressure monitoring averages).39
Antihypertensive treatment may be warranted in patients with masked hypertension, but 
there are currently no randomized trials that have evaluated this strategy, and the best 
method to identify people with masked hypertension has not been established. There is a 
substantial diagnostic overlap between prehypertension and masked hypertension. In one 
study, 83.8% of participants with masked hypertension had prehypertension and 34.1% of 
participants with prehypertension had masked hypertension: the prevalence of masked 
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hypertension was only 3.9% in participants with normal clinic blood pressure (<120/80 mm 
Hg).40 Evidence-based guidelines for detecting, evaluating, and managing masked 
hypertension are needed.
LIMITATIONS OF AMBULATORY BLOOD PRESSURE MONITORING
The limitations of ambulatory blood pressure monitoring include potential discomfort during 
nighttime periods, the reluctance of some patients to undergo ambulatory blood pressure 
monitoring especially for repeat measurement, occasionally not being able to detect genuine 
artefactual measurements, and the limited available of ambulatory blood pressure monitoring 
in general practice.16 Reimbursement issues are a considerable contributor to ambulatory 
blood pressure monitoring's limited availability in some regions, including the United States, 
where the only currently reimbursable indication from Medicare is suspected white-coat 
hypertension: private insurers have more indications, but these vary from carrier to carrier. 
Many countries outside the United States do not provide any reimbursement.16
However, while it is true that the cost of ambulatory blood pressure monitoring equipment 
will likely be more expensive than a simple cuff blood pressure measurement in the short 
term, it may be more cost effective in the long term because of the avoidance of multiple 
clinic visits during which cuff blood pressure readings would be obtained and the cost 
savings from not treating patients who do not actually need antihypertensive medication 
since white-coat hypertension was ruled out by early ambulatory blood pressure monitoring. 
As previously noted, this rationale, discussed by Lovibond et al,32 formed the basis of the 
United Kingdom's 2011 guidelines for the clinical management of primary hypertension in 
adults.9 Cost-effectiveness and reimbursement issues concerning ambulatory blood pressure 
monitoring in the United States have certainly been discussed in the literature,41–44 and 
evidence of cost-effectiveness reported. However, reimbursement is still a difficult issue. As 
Bloch and Basile44 observed, "Even if we believe that routine use of [ambulatory blood 
pressure monitoring] will better secure the diagnosis of hypertension and save money in the 
long-run, there is simply no group that is appropriately incentivized to make the needed 
short-term investment required to make it practical in our system." It is nonetheless hoped 
that, over time, changes in reimbursement structures may facilitate the wider use of 
ambulatory blood pressure monitoring.
Not all hypertension guidelines contain information on the use of ambulatory blood pressure 
monitoring, which may lead physicians who tend to rely on a particular guideline that does 
not contain this information to believe that ambulatory blood pressure monitoring is not of 
importance in their clinical practice. Such guidelines include the recent report from the JNC 
8 panelists,45 who noted in the Supplemental Information available on-line that their report 
does not comment on ambulatory blood pressure monitoring because it was not used in the 
randomized controlled trials used in their evidence review, and "conducting a separate 
evidence-based review to look at this issue was beyond the scope" of their report.46
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While the large majority of patients with hypertension are managed in primary care settings, 
primary care doctors may be able to refer their patients to an external service, including 
specialist clinics and pharmacy-based services.16
The European Society of Hypertension has established accredited Centres of Excellence in 
hypertension,47 and the American Society of Hypertension has designated certain centers as 
Hypertension Centers that are well-placed to assist patients with difficult-to-treat 
hypertension and their health care providers.48 These initiatives "can ensure the application 
of [ambulatory blood pressure monitoring] in many patients with complex hypertension."14
One study conducted in Ireland to explore additional ways to increase accessibility to 
ambulatory blood pressure monitoring compared data from patients attending primary care 
sites with those attending pharmacies between 2007 and 2013.49 The blood pressure 
characteristics of patients with ambulatory blood pressure recorded in pharmacies were 
similar to those recorded in primary care practice settings, supporting the feasibility of 
performing ambulatory blood pressure monitoring in pharmacies, thus increasing availability 
of the technique to the large hypertensive population.
With regard to educating primary care physicians about ambulatory blood pressure 
monitoring and clinical practice guidelines related to its employment, greater outreach and 
educational activities by hypertension professional societies may be helpful. This could be 
done via targeted Editorials in the societies' journals and also by increased educational 
opportunities at their annual meetings.
FUTURE DIRECTIONS
The practice of pharmacological chronotherapy may increase in coming years given 
increasing interest in this approach. Chronotherapy involves "the timing of hypertension 
medications to endogenous circadian rhythm determinants of the 24-h [blood pressure] 
pattern."50 It is now known that there are clinically meaningful treatment-time differences in 
responses (both therapeutically beneficial responses and adverse effects) to drugs in multiple 
classes: for example, calcium channel blockers are more effective when taken at bedtime 
than in the morning. Increasing attention is being paid to the importance of reducing sleep-
time blood pressure, since mean sleep-time blood pressure is the most significant prognostic 
marker of cardiovascular morbidity and mortality.51 One study included over 3,000 
participants during a median follow-up period of more than 5 years,51 and reported that 
progressive decrease in sleep-time blood pressure was the most significant predictor of 
event-free survival. The most beneficial time for a patient to take antihypertensive 
medication, perhaps evening time rather than first thing in the morning, can be determined 
by ambulatory blood pressure monitoring.
CONCLUSION
The technique of ambulatory blood pressure monitoring is important in the diagnosis and 
management of hypertension. It enables white-coat hypertension to be ruled out, thus 
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precluding patients who do not need interventions at that time from being prescribed such 
intervention, while also identifying those individuals who should commence 
antihypertensive therapy. It also facilitates the assessment of blood pressure during sleep-
time: a non-dipping pattern and nocturnal hypertension are strongly associated with 
increased cardiovascular morbidity and mortality. The various blood pressure categorizations 
afforded by ambulatory blood pressure monitoring are valuable for clinical management of 
high blood pressure since they increase accuracy for diagnosis and the prediction of 
cardiovascular risk.
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1. Ambulatory blood pressure monitoring allows BP readings to be taken across a 
24-hour period.
2. Several guidelines exist for the use of ambulatory blood pressure monitoring in 
clinical practice.
3. Using ambulatory blood pressure monitoring to rule out white-coat hypertension 
prevents patients from being prescribed unnecessary antihypertensive 
medications.
4. Ambulatory blood pressure monitoring also allows measurement of nocturnal 
BP, an increasingly important prognostic parameter for cardiovascular disease 
risk.
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FIGURE. Graph of 24-Hour Ambulatory Blood Pressure Monitoring Data
The shaded portion indicates the sleep period. This patient had 8 measurements recorded 
during sleep and 29 measurements while awake. The overall average is 130/79 mm Hg. 
Awake average is 134/82 mm Hg, and sleep average is 115/70 mm Hg, for a nocturnal 
systolic BP dip of 14%.
Turner et al. Page 13









































Turner et al. Page 14
TABLE
Guidelines/Consensus Documents/Position Papers/Scientific Statements from Professional Societies related to 


















New recommendations for the use of ambulatory blood pressure
monitoring in the diagnosis of hypertension.
JCS Joint Working
Group (2012)12
Guidelines for the clinical use of 24 hour ambulatory blood pressure
monitoring (ABPM) (JCS 2010).
Hermida et al
(2013)13
2013 ambulatory blood pressure monitoring recommendations for the
diagnosis of adult hypertension, assessment of cardiovascular and other
hypertension-associated risk, and attainment of therapeutic goals.
O'Brien et al
(2013)14
European Society of Hypertension position paper on ambulatory blood
pressure monitoring.
Flynn et al (2014)15 Ambulatory blood pressure monitoring in children and adolescents: a
scientific statement from the American Heart Association.
Parati et al (2014)16 European Society of Hypertension practice guidelines for ambulatory
blood pressure monitoring.
[NOTE: This paper is from the same Working Group as the O'Brien et
al14 paper, and represents "an updated schematic summary of the most
important aspects related to the use of ABPM in daily practice."16]
Abbreviations: ESH, European Society of Hypertension. JCS, Japanese Circulation Society. NICE, National Institute for Health and Care 
Excellence.
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